TH63184B - Bioactive peptides - Google Patents

Abstract

DC60 (30/08/45) Thirty pure and bioactive peptides are disclosed, where nucleic acids are coded sequences for bioactive peptides and pharmaceutical formulations produced. From there it will be opened as well.

Claims (27)

------03/11/2560------(OCR) Page 1 of 1 page. Claims. 1. Pharmaceutical composition consisting of a peptide with the amino acid sequence YSL (SEQ ID No. 16). 2. Method for preparing a pharmaceutical compound consisting of the preparation of the peptides as specified in Patent 1 and the combination of such peptides with a pharmaceutically acceptable carrier. 3. The peptide as specified in claim 1 for therapeutic use. 4. The use of the peptide as specified in claim 1 in pharmaceutical manufacturing for optimization of at least one of the following conditions: immune activity and cancer growth. 5. The peptide as specified in claim 1 for use in optimizing at least one of the following conditions: immune activity and cancer growth. 6. The use under claim 4 or 5 where the cancer is liver cancer or melanoma growth. 7. A pure purified peptide incorporating the amino acid sequence SEQ ID 1. 8. The peptide as specified in claim 7 where such peptide is optimized for at least one of the following conditions: immune activity, hepatitis, hepatitis B infection, and cancer growth. 9. A pharmaceutical composition incorporating a pure purified peptide incorporating the amino acid sequence SEQ ID 1. 10. A method for preparing pharmaceutical components comprising the preparation of a purely purified peptide incorporating the amino acid sequence SEQ ID No. 1 and the mixing of such purely purified peptide with a pharmaceutically acceptable carrier. 11. Purely purified peptide incorporating the amino acid sequence SEQ ID No. 1 for therapeutic use. 12. Use of purely purified peptide incorporating the amino acid sequence SEQ ID No. 1 for the production of pharmaceuticals for optimization of immune activity, hepatitis, or cancer growth. 13. Purely purified peptide incorporating the amino acid sequence SEQ ID No. 1 for use in optimizing immune activity, hepatitis, or cancer growth. ------------ 1. Purely purified peptide incorporating a selected amino acid sequence. 1. A group containing SEQ ID 1-30. 2. A truly purified peptide as per claim 1, which can be optimized for at least one of the following conditions: immune activity, hepatitis, hepatitis B infection, glomerulonephritis extent, and malignant growth. 3. A truly purified peptide, essentially composed of an amino acid sequence selected from the group containing SEQ ID 1-30. 4. A truly purified peptide as per claim 3, which can be optimized for at least one of the following conditions: immune activity, hepatitis, hepatitis B infection, extent of glomerulonephritis, and malignant growth. 5. Truly pure peptides, composed of selected amino acid sequences from groups containing SEQ ID numbers 1-30. 6. Truly pure peptides, primarily composed of functional derivatives of biologically active peptides, contain selected amino acid sequences from groups with SEQ ID numbers 1-30. 7. A truly purified peptide as per claim 6, which can be optimized for at least one of the following conditions: immune activity, hepatitis, hepatitis B infection, extent of glomerulonephritis, and malignant growth. 8. Truly pure peptides, primarily composed of functional derivatives of biologically active peptides, will have amino acid sequences selected from groups containing SEQ ID numbers 1-30. 9. A truly purified peptide as per claim 8, which can be optimized for at least one of the following conditions: immune activity, hepatitis, hepatitis B infection, extent of glomerulonephritis, and malignant growth. 10. Truly pure peptides, consisting of functional derivatives of biologically active peptides, will have a selected amino acid sequence from a group containing SEQ ID numbers 1-30. 11. A truly purified peptide as per claim 10, which such peptide1 can be optimized for at least one of the following conditions: immune activity, infection, hepatitis, hepatitis B infection, extent of nephritis, and malignant growth. 12. A genetic vector consists of a nucleotide sequence that encodes a peptide, which in turn contains a sequence of amino acids selected from a group containing SEQ ID numbers 1-30. 13. A vector pursuant to claim 12, whereby the peptide can be optimized for at least one of the following conditions: immune activity, hepatitis, hepatitis B infection, extent of glomerulonephritis, and malignant growth. 14. A genetic vector consists of a nucleotide sequence that encodes a peptide, and importantly, a sequence of amino acids selected from a group containing SEQ ID numbers 1-30. 15. A genetic vector consists of a nucleotide sequence that encodes a peptide, which then contains a functional derivative of a biologically active peptide. This biologically active peptide will have an amino acid sequence selected from a group containing SEQ ID numbers 1-30. 16. A genetic vector consists of a nucleotide sequence that encodes a peptide, which is essentially composed of functional derivatives of an amino acid sequence selected from a group containing SEQ IDs 1-30. 17. Microorganisms containing genetic material consisting of a nucleic acid sequence that encodes a peptide; this peptide comprises functional derivatives of biologically active peptides; these biologically active peptides have an amino acid sequence selected from a group containing SEQ ID numbers 1-30. 18. Pharmaceutical mixtures containing pure peptides composed of selected amino acid sequences from groups containing SEQ ID numbers 1-30. 19. Pharmaceutical compounds consisting of pure peptides comprising functional derivatives of biologically active peptides; these biologically active peptides have an amino acid sequence selected from a group containing SEQ ID numbers 1-30. 20. Pharmaceutical mixtures containing pure peptides, primarily composed of functional derivatives of biologically active peptides, these biologically active peptides have amino acid sequences selected from groups containing SEQ ID 1-30. 21. Pharmaceutical compounds are composed of pure peptides, primarily functional derivatives of biologically active peptides. These biologically active peptides have amino acid sequences selected from groups containing SEQ ID numbers 1-30. 22. The method of pharmaceutical compound formulation involves assembling a truly pure peptide consisting of an amino acid sequence selected from groups with SEQ ID numbers 1-30, and then mixing this truly pure peptide with a pharmaceutically acceptable carrier. 23. The method of compounding pharmaceutical formulations involves assembling compounds under the condition that the peptides are of truly pure quality, composed of an amino acid sequence selected from a group containing SEQ ID numbers 1-30. 24. The method of pharmaceutical compound formulation involves the combination of a truly pure peptide containing a selected amino acid sequence, which is a functional derivative of a biologically active peptide. This biologically active peptide will have an amino acid sequence selected from a group containing SEQ ID 1-30, and the truly pure peptide is compounded using a pharmaceutically acceptable carrier. 25. The pharmaceutical compound formulation method involves the use of a truly pure peptide, significantly composed of a selected amino acid sequence, which is a functional derivative of a biologically active peptide. This biologically active peptide will have an amino acid sequence selected from a group containing SEQ ID 1-30, and the truly pure peptide is compounded with a pharmaceutically acceptable carrier. 26. Utilization of pure peptides, comprising selected amino acid sequences from groups containing SEQ IDs 1-30, for the preparation of pharmaceutical compounds for human treatment. 27. Utilization of pure peptides comprising functional derivatives of bioactive peptides. Such bioactive peptides will have amino acid sequences selected from groups containing SEQ ID 1-30, for the preparation of pharmaceutical compounds for human treatment.